John Gibson
Analyst · Johnson Rice
Thank you, Nick, and good morning everybody. Our third quarter performance reflects the execution of our strategy to accelerate sales performance for chemistry technology and data analytics and focus on resolving our remaining legacy issues. I'll talk about all this. We've been working very hard through third quarter to grow revenues. I'm pleased to report that our revenues for the third quarter up approximately 11% compared to the second quarter. When we review revenue growth from some of the larger oilfield service companies, we see modest gains versus the second quarter. We believe our quarter-over-quarter results compared favorably against our peers. Mike Borton is going to walk you through the financial numbers and in more detail a little later in the call. Our execution of our sales strategy has been a priority for us as we emerge from COVID. And we've already seen a positive impact. During our second quarter call, I communicated that we had trimmed cost in certain areas to reinvest in our sales team. We've executed on that decision and I can report that we brought on board 11 new sales professionals to date, eight new members supporting the chemistry business and three new people for data analytics. These folks are all highly experienced professionals with proven track record and substantial sales quotas in their previous roles and hopefully in the role here as well. Their industry relationships will help us execute our go-to-market strategy. We continue to reinvigorate our sales efforts with ECT and the impact has been demonstrable growth and diversity of revenues for that segment. We were also fortunate in the third quarter as Hurricane Ida passed almost directly over a rail spur in Louisiana. We suffered minimal damage there and we were able to continue service, which was a benefit to the industry and in particular our customers. We believe that our operational continuity presents us with upside for that facility and we expect to see strong performance over the next few quarters in ratio. And in addition to the new sales professionals that I mentioned, our ProChem business has also signed four strategic agreements with manufacturing representation companies. Ultimately, these agreements give us immediate access to a sizable sales force and a broad geography. These alliances are key to our strategy of utilizing an indirect sales channel to increase targeting opportunities. We certainly didn't invent this approach. There are several well established companies like Clorox, Gojo, and 3M that leverage the model successfully and we are looking to do the same. We believe this particular strategy has a lot to offer us in terms of minimizing our cost to execute versus potential returns. Ryan is going to give you more detail around the sales and revenue transfer ECT as well as some additional highlights into ProChem’s milestones this past quarter. ECT and ProChem had certainly had a lot of activity over the third quarter not to be outdone, JP3 issued two significant press releases on product deployment and new patent pending technology. The first announcement was for the launch of the AIDA application, which we're very excited about, machine learning AI based application. The later release concerned international certification for our online analyzers, which we've all been anticipating. I will let Koid give you more color around those releases. We believe that those two deployments will help us gain ground on our stated goals of increasing international sales, and overall profitable revenue growth. Now we continue to see a decent pace of consolidations in M&A activity interspace, examples include next year's acquisition of Alamo Pressure Pumping, ProFrac’s acquisition of FTSI, and recently Wilks merger with Dawson Geophysical. We are actively evaluating the M&A market and looking for opportunities that fit within our criteria for success. There are three main criteria, we would consider only deals that are quickly accretive. With deals that involve cash requirements that will be supported by the market and shareholders. And finally, the deal has to have the potential to enhance our sustainability objectives. The successful execution of this sustainability objectives is a critical path to our success as I believe we're now on a path to a widespread adoption in our industry of an environmental culture across the whole of the industry. Today, strong safety culture and the demonstrable metrics have become table stakes in our industry without them, you're not considered a bidder. Similarly, ESG performance will become another factor that defines what desirable business partners look like. There is no doubt that the ESG footprint influences a company's access to capital. We see strong adoption and philosophical alignment at the board and C-suite levels. But there is still some amount of latency and translation to buying habits at the operational levels. The industry's adoption of ESG principles and the establishment and the emergence of an environmental culture is likely to occur at a rapid pace in 2022. Flotek is well positioned to be the partner of choice for effective responsible chemistry and data solutions. These changes that we made around our sales strategy capacity, as well as the groundwork relating with JP3 will be key to differentiating ourselves in the marketplace for the evolving environmental cultures of our customers. Supply chain uncertainty is a topic that also gotten considerable media attention of late, we continue to watch developments concerning the possibility of sanctions against China. If prolonged sanctions could change the drilling industry demand dramatically, China currently produces and exports considerable quantities of polyacrylamide and barium sulfate, both widely used in the OFS industry and by operators. Additionally, inflationary pressures and transportation constraints have the potential to impact our customers pushing prices up and contributing to sourcing delays. These factors increased complexity, they also present opportunities for us to work with customers and structure mutually advantageous outcomes. We've implemented processes that are designed to help us monitor and to adapt to many of these macro environmental factors. We've made investments in strengthening our own supply chain and logistics function. We've implemented system designed to more seamlessly communicate sales forecast with supply and we have a team that is experienced in international agreements. Now, most of my comments so far really highlighted accomplishments of what we've done in the quarter around our business. And what we see as the path forward, however, I want to take just a moment to discuss one of our legacy matters. As you know, when I started in 2020, I inherited a type of terpene contract with Florida Chemical company that was well in excess of our need. At the end of 2020, we booked to 9.4 million of accrued liability for losses we expected to incur as a result of that contract. Earlier this year, we became involved in litigation with Florida chemical and ADM. its parent company and as a result of that contract and our request for an audit, we pursued the litigation. In the course of the litigation, we were able to find a commercial counterpart at IBM and we were successful in bringing the matter to a close and we settled the litigation last month. As a part of the settlement we agreed to pay Florida Chemical 1.7 5 million and the terpene contract is confirmed terminated and with it the obligation to purchase an additional 10.5 million pounds of terpene. This allows us to release the 9.4 million accrued liability as well, which Mike will tell you more about in his comments. We're grateful to IBM for their willingness to engage with us in a business negotiation. And we're happy to put this legacy matter behind us. Now with that, I'd like to turn it over to TengBeng to cover data analytics. TengBeng ?